Cargando…

A novel prognostic signature of immune-related lncRNA pairs in lung adenocarcinoma

Lung adenocarcinoma (LUAD) is the most common subtype of lung cancer, but the prognosis of LUAD patients remains unsatisfactory. Here, we retrieved the RNA-seq data of LUAD cohort from The Cancer Genome Atlas (TCGA) database and then identified differentially expressed immune-related lncRNAs (DEirln...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yang, Wu, Qiuhong, Fan, Xuejiao, Li, Wen, Li, Xiaogang, Zhu, Hui, Zhou, Qinghua, Yu, Jinming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8373953/
https://www.ncbi.nlm.nih.gov/pubmed/34408216
http://dx.doi.org/10.1038/s41598-021-96236-4
_version_ 1783740015030829056
author Liu, Yang
Wu, Qiuhong
Fan, Xuejiao
Li, Wen
Li, Xiaogang
Zhu, Hui
Zhou, Qinghua
Yu, Jinming
author_facet Liu, Yang
Wu, Qiuhong
Fan, Xuejiao
Li, Wen
Li, Xiaogang
Zhu, Hui
Zhou, Qinghua
Yu, Jinming
author_sort Liu, Yang
collection PubMed
description Lung adenocarcinoma (LUAD) is the most common subtype of lung cancer, but the prognosis of LUAD patients remains unsatisfactory. Here, we retrieved the RNA-seq data of LUAD cohort from The Cancer Genome Atlas (TCGA) database and then identified differentially expressed immune-related lncRNAs (DEirlncRNAs) between LUAD and normal controls. Based on a new method of cyclically single pairing along with a 0-or-1 matrix, we constructed a novel prognostic signature of 8 DEirlncRNA pairs in LUAD with no dependence upon specific expression levels of lncRNAs. This prognostic model exhibited significant power in distinguishing good or poor prognosis of LUAD patients and the values of the area under the curve (AUC) were all over 0.70 in 1, 3, 5 years receiver operating characteristic (ROC) curves. Moreover, the risk score of the model could serve as an independent prognostic factor for patients with LUAD. In addition, the risk model was significantly associated with clinicopathological characteristics, tumor-infiltrating immune cells, immune-related molecules and sensitivity of anti-tumor drugs. This novel signature of DEirlncRNA pairs in LUAD, which did not require specific expression levels of lncRNAs, might be used to guide the administration of patients with LUAD in clinical practice.
format Online
Article
Text
id pubmed-8373953
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-83739532021-08-20 A novel prognostic signature of immune-related lncRNA pairs in lung adenocarcinoma Liu, Yang Wu, Qiuhong Fan, Xuejiao Li, Wen Li, Xiaogang Zhu, Hui Zhou, Qinghua Yu, Jinming Sci Rep Article Lung adenocarcinoma (LUAD) is the most common subtype of lung cancer, but the prognosis of LUAD patients remains unsatisfactory. Here, we retrieved the RNA-seq data of LUAD cohort from The Cancer Genome Atlas (TCGA) database and then identified differentially expressed immune-related lncRNAs (DEirlncRNAs) between LUAD and normal controls. Based on a new method of cyclically single pairing along with a 0-or-1 matrix, we constructed a novel prognostic signature of 8 DEirlncRNA pairs in LUAD with no dependence upon specific expression levels of lncRNAs. This prognostic model exhibited significant power in distinguishing good or poor prognosis of LUAD patients and the values of the area under the curve (AUC) were all over 0.70 in 1, 3, 5 years receiver operating characteristic (ROC) curves. Moreover, the risk score of the model could serve as an independent prognostic factor for patients with LUAD. In addition, the risk model was significantly associated with clinicopathological characteristics, tumor-infiltrating immune cells, immune-related molecules and sensitivity of anti-tumor drugs. This novel signature of DEirlncRNA pairs in LUAD, which did not require specific expression levels of lncRNAs, might be used to guide the administration of patients with LUAD in clinical practice. Nature Publishing Group UK 2021-08-18 /pmc/articles/PMC8373953/ /pubmed/34408216 http://dx.doi.org/10.1038/s41598-021-96236-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Liu, Yang
Wu, Qiuhong
Fan, Xuejiao
Li, Wen
Li, Xiaogang
Zhu, Hui
Zhou, Qinghua
Yu, Jinming
A novel prognostic signature of immune-related lncRNA pairs in lung adenocarcinoma
title A novel prognostic signature of immune-related lncRNA pairs in lung adenocarcinoma
title_full A novel prognostic signature of immune-related lncRNA pairs in lung adenocarcinoma
title_fullStr A novel prognostic signature of immune-related lncRNA pairs in lung adenocarcinoma
title_full_unstemmed A novel prognostic signature of immune-related lncRNA pairs in lung adenocarcinoma
title_short A novel prognostic signature of immune-related lncRNA pairs in lung adenocarcinoma
title_sort novel prognostic signature of immune-related lncrna pairs in lung adenocarcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8373953/
https://www.ncbi.nlm.nih.gov/pubmed/34408216
http://dx.doi.org/10.1038/s41598-021-96236-4
work_keys_str_mv AT liuyang anovelprognosticsignatureofimmunerelatedlncrnapairsinlungadenocarcinoma
AT wuqiuhong anovelprognosticsignatureofimmunerelatedlncrnapairsinlungadenocarcinoma
AT fanxuejiao anovelprognosticsignatureofimmunerelatedlncrnapairsinlungadenocarcinoma
AT liwen anovelprognosticsignatureofimmunerelatedlncrnapairsinlungadenocarcinoma
AT lixiaogang anovelprognosticsignatureofimmunerelatedlncrnapairsinlungadenocarcinoma
AT zhuhui anovelprognosticsignatureofimmunerelatedlncrnapairsinlungadenocarcinoma
AT zhouqinghua anovelprognosticsignatureofimmunerelatedlncrnapairsinlungadenocarcinoma
AT yujinming anovelprognosticsignatureofimmunerelatedlncrnapairsinlungadenocarcinoma
AT liuyang novelprognosticsignatureofimmunerelatedlncrnapairsinlungadenocarcinoma
AT wuqiuhong novelprognosticsignatureofimmunerelatedlncrnapairsinlungadenocarcinoma
AT fanxuejiao novelprognosticsignatureofimmunerelatedlncrnapairsinlungadenocarcinoma
AT liwen novelprognosticsignatureofimmunerelatedlncrnapairsinlungadenocarcinoma
AT lixiaogang novelprognosticsignatureofimmunerelatedlncrnapairsinlungadenocarcinoma
AT zhuhui novelprognosticsignatureofimmunerelatedlncrnapairsinlungadenocarcinoma
AT zhouqinghua novelprognosticsignatureofimmunerelatedlncrnapairsinlungadenocarcinoma
AT yujinming novelprognosticsignatureofimmunerelatedlncrnapairsinlungadenocarcinoma